1. Olgin, J. E.; Zipes, D. P. In Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed.; Braunwald, E., Zipes, D. P., Libby, P., Eds.; W B. Saunders: Philadelphia, PA, 2001, pp 815-889.

2. Iqbal, M. B.; K Taneja, A.; Lip, G. Y; Flather, M. Br. Med. J. 2005, 330, 238-243.

3. Clements-Jewery, H.; Curtis, M. J. In Cardiac Drug Development Guide; Pugsley, M. K., Ed.; Humana Press: Totowa, NJ, 2003, pp 203-225.

4. Wilde, A. A.; Bezzina, C. R. Heart 2005, 91, 1352-1358.

5. Roden, D. M.; Balser, J. R.; George, A. L., Jr.; Anderson, M. E. Annu. Rev Physiol. 2002, 64, 431-475.

6. George, A. L., Jr. J. Clin. Invest. 2005, 115, 1990-1999.

7. Roden, D. M.; George, A. L., Jr. Annu. Rev. Med. 1996, 47, 135-148.

8. Catterall, W A. Annu Rev. Cell Dev. Biol. 2000, 16, 521-555.

9. Tamargo, J.; Caballero, R.; Gomez, R.; Valenzuela, C.; Delpon, E. Cardioovasc. Res. 2004, 62, 9-33.

10. DiFrancesco, D. Curr. Med. Res. Opin. 2005, 21, 1115-1122.

11. Zipes, D. P. J. Cardiovasc. Electrophysiol. 2003, 14, 902-912.

12. Antzelevitch, C. Curr. Opin. Cardiol. 2001, 16, 1-7.

13. Gonzalez, J. E.; Oades, K.; Leychkis, Y; Harootunian, A.; Negulescu, P. A. Drug Disc. Today 1999, 4, 431-439.

14. Norinder, U. SAR QSAR Environ. Res. 2005, 16, 1-11.

16. Wijffels, M. C.; Kirchhof, C. J.; Dorland, R.; Allessie, M. A. Circulation 1995, 92, 1954-1968.

17. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. 1989, 321, 406-412.

18. Roden, D. M. In Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 11th ed.; Brunton, L. L., Lazo, J. S., Parker, K. L., Eds.; McGraw-Hill: New York, 2005, pp 899-932.

19. Vaughan Williams, E. M. J. Clin. Pharmacol. 1992, 32, 964-977.

20. The Sicilian Gambit. Circulation 1991, 84, 1831-1851.

21. Bardy, G. H.; Lee, K. L.; Mark, D. B.; Poole, J. E.; Packer, D. L.; Boineau, R.; Domanski, M.; Troutman, C.; Anderson, J.; Johnson, G. et al. N. Engl. J. Med. 2005, 352, 225-237.

22. Luderitz, B. J. Interv. Card. Electrophysiol. 2003, 9, 75-83.

23. Koufaki, M.; Calogeropoulou, T; Rekka, E.; Chryselis, M.; Papazafiri, P.; Gaitanaki, C.; Makriyannis, A. Bioorg. Med. Chem. 2003, 11, 5209-5219.

24. Lee, K.; Lee, J. Y; Kim, H. Y; Kwon, L. S.; Shin, H. S.; Tanabe, S.; Kozono, T; Park, S. D.; Chung, Y S. J. Cardiovasc. Pharmacol. 1998, 31, 609-617.

25. Bauer, A.; Koch, M.; Kraft, P.; Becker, R.; Kelemen, K.; Voss, F; Senges, J. C.; Gerlach, U.; Katus, H. A.; Schoels, W Basic Res. Cardiol. 2005, 100, 270-278.

26. Regan, C. P.; Wallace, A. A.; Cresswell, H. K.; Atkins, C. L.; Lynch, J. J. J. Pharmacol. Exp. Ther. 2006, 316, 727-732.

27. Matsuda, T.; Takeda, K.; Ito, M.; Yamagishi, R.; Tamura, M.; Nakamura, H.; Tsuruoka, N.; Saito, T; Masumiya, H.; Suzuki, T et al. J. Pharmacol. Sci. 2005, 98, 33-40.

28. Takahara, A.; Sugiyama, A.; Dohmoto, H.; Yoshimoto, R.; Hashimoto, K. Eur. J. Pharmacol. 2000, 398, 107-112.

29. Carlsson, B.; Singh, B. N.; Temciuc, M.; Nilsson, S.; Li, Y. L.; Mellin, C.; Malm, J. J. Med. Chem. 2002, 45, 623-630.

30. Roy, D.; Rowe, B. H.; Stiell, I. G.; Coutu, B.; Ip, J. H.; Phaneuf, D.; Lee, J.; Vidaillet, H.; Dickinson, G.; Grant, S. et al. J. Am. Coll. Cardiol. 2004, 44, 2355-2361.

31. Opincariu, M.; Varro, A.; Iost, N.; Virag, L.; Hala, O.; Szolnoki, J.; Szecsi, J.; Bogats, G.; Szenohradszky, P.; Matyus, P. et al. Curr. Med. Chem. 2002, 9, 41-46.

32. Bril, A.; Forest, M. C.; Cheval, B.; Faivre, J. F Cardiovasc. Res. 1998, 37, 13-40.

33. Wu, L.; Shryock, J. C.; Song, Y; Li, Y; Antzelevitch, C.; Belardinelli, L. J. Pharmacol. Exp. Ther. 2004, 310, 599-605.

34. Pankucsi, C.; Banyasz, T; Magyar, J.; Gyonos, I.; Kovacs, A.; Varro, A.; Szenasi, G.; Nanasi, P. P. Naunyn Schmiedebergs Arch. Pharmacol. 1997, 355, 398-405.

35. Qi, X.; Varma, P; Newman, D.; Dorian, P. Circulation 2001, 104, 1544-1549.

36. Xing, D.; Kjolbye, A. L.; Nielsen, M. S.; Petersen, S.; Harlow, K. W; Holstein-Rathlou, N. H.; Martins, J. B. J. Cardiovasc. Electrophysiol. 2003, 14, 510-520.

37. Decher, N.; Lang, H. J.; Nilius, B.; Bruggemann, A.; Busch, A. E.; Steinmeyer, K. Br. J. Pharmacol. 2001, 134, 1467-1479.

38. Hobai, I. A.; O'Rourke, B. Exp. Opin. Investig. Drugs 2004, 13, 653-664.

39. Gumina, R. J.; Buerger, E.; Eickmeier, C.; Moore, J.; Daemmgen, J.; Gross, G. J. Circulation 1999, 100, 2519-2526.

40. Raitt, M. H.; Connor, W E.; Morris, C.; Kron, J.; Halperin, B.; Chugh, S. S.; McClelland, J.; Cook, J.; MacMurdy, K.; Swenson, R. et al. JAMA 2005, 293, 2884-2891.

41. Xiao, Y F; Kang, J. X.; Morgan, J. P; Leaf, A. Proc. Natl. Acad. Sci. USA 1995, 92, 11000-11004.

42. Honore, E.; Barhanin, J.; Attali, B.; Lesage, F; Lazdunski, M. Proc. Natl. Acad. Sci. USA 1994, 91, 1937-1941.

43. Ramaswamy, K.; Hamdan, M. H. Crit. Care Med. 2000, 28, N151-NN15.

44. Hondeghem, L. M. Circulation 1987, 75, 514-520.

45. Carmeliet, E. Physiol. Rev. 1999, 79, 917-1017.

46. Yong, S. L.; Xu, R.; McLarnon, J. G.; Zolotoy, A. B.; Beatch, G. N.; Walker, M. J. A. J. Pharmacol. Exp. Ther. 1999, 289, 236-244.

47. Bain, A. L.; Barrett, T D.; Beatch, G. N.; Fedida, D.; Hayes, E. S.; Plouvier, B.; Pugsley, M. K.; Walker, M. J. A.; Walker, M. L.; Wall, R. A. et al.

48. Walker, M. J. A.; Guppy, L. J. In Cardiac Drug Development Guide; Pugsley, M. K., Ed.; Humana Press: Totowa, NJ, 2003, pp 175-201.

49. Ribeiro, W; Ifa, D. R.; Corso, G.; Salmon, J.; Moraes, L. A.; Eberlin, M. N.; De Nucci, G. J. Mass Spectrom. 2001, 36, 1133-1139.

50. Barrett, T D.; Hayes, E. S.; Yong, S. L.; Zolotoy, A. B.; Abraham, S.; Walker, M. J. A. Eur. J. Pharmacol. 2000, 398, 365-374.


Michael J A Walker is an emeritus professor at the University of British Columbia and has spent over 30 years in the Department of Pharmacology and Therapeutics there. Michael Walker has been working for over 25 years in the area of antiarrhythmic research and has published widely in this, and other areas. His research interests, centered on the discovery of new antiarrhythmic drugs, led to the founding of a biotech company whose research goal was the discovery of new antiarrhythmic drugs, particularly for prevention of the ventricular fibrillation that occurs in the acute phase of a heart attack. That company, now known as Cardiome Pharma Corp., is currently finishing a series of phase III clinical trials with one of their discoveries, RSD1235, in preparation for a NDA. The drug's first use is expected to be as an intravenous drug for the termination of atrial fibrillation of recent onset.

Petsy P S So obtained a BSc Honours degree in the Department of Pharmacology and Therapeutics at the University of British Columbia, and is currently a PhD student working under the supervision of Dr Paul Dorian at the University of Toronto. Petsy is currently working on the antiarrhythmic actions of potassium channel blockers and looks forward to future antiarrhythmic drug research.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 729-762

Was this article helpful?

0 0

Post a comment